As a 1p/19q codeletion, MGMT promoter methylation and IDH1 mutation is an important marker for the prognostic evaluation of glioma patients, and we investigated expression of HIC2 and this clinicopathologic feature. This evidence concerns the gene MGMT and central nervous system cancer.